Actively Recruiting US Interventional Trials in ALS

To provide potentially constructive direction to those interested in the clinical investigation of ALS, here are some novel (and not so novel) treatments that are currently being (or will be) assessed in US-based trials, according to the NIH database.

• Arimoclomol: A small molecule that upregulates cellular "molecular chaperones," which are believed to enhance responses to cellular stress. Positive preclinical data in ALS rodent models have been reported.
• E0302 (mecobalamin): A form of vitamin B12.
• GSK1223249: A humanized monoclonal antibody against Nogo-A, a neurite-outgrowth inhibitor.
• SB509: A zinc finger DNA-binding protein transcription factor that is designed to upregulate the expression of VEGF.

Actively recruiting (or not-yet-recruiting) US-based trials in ALS:

N.B. Contact information for trial enrollment is available through the links.

ALS = amyotrophic lateral sclerosis; SOD1 = superoxide dismutase 1; VEGF = vascular endothelial cell growth factor.

* Patients with SOD1-positive, familial ALS.